Background: Microfocused ultrasound with visualization (MFU-V) has become a safe and effective means to tighten skin and subdermal structures by optimizing the amount of joule energy and treatment tissue planes for improved customization for the individual patient. To date, there have been an absence of split treatments to verify algorithms. Objectives: The aims of this institutional review board-approved investigation and clinical experience were to clarify the safety and efficacy of current treatment guidelines. Methods: This split-face investigation quantified tissue displacement at the marionette folds after single treatments of 2 different treatment densities or number of lines and 2 vs 3 planes of treatment with matched-orientation photography, elasticity measurements, subjective assessments by patient (SGAIS), and blinded-investigator global investigation (IGIAS) analyses at baseline, 180 days post treatment (D180), and 360 days post treatment (D360). Clinical studies, utilizing these algorithms to treat regional areas of the forehead, periorbitum, face, neck, and décolleté, were analyzed by (IGIAS) assessment, pain scoring, and incidence of complications and side effects at D180 and D360. Results: Post hoc analyses at D180 and D360 in pilot studies 1 and 2 demonstrated greater tissue displacements, elasticity measurement, and pain scores, supported by SGAIS and IGAIS assessment with the use of higher amounts of joule energy and treatment planes than those used on the contralateral reference marionette folds at D180 and D360. Pain scores after use of each transducer or at the end of the procedure showed variability at different regional areas with more discomfort noted with treatments at the deepest and most superficial tissue planes. There were no major adverse reactions and minimal short-termed side effects in the entire study. Conclusions: Optimization, customization, and safety were observed with the use of current MFU-V algorithms as clarified by the findings in this investigation. Further investigations with multiple sessions will be required to advance this unique noninvasive technology for tissue lifting.
and targets zones in the dermis, subdermal fibers, and superficial musculoaponeurotic system (SMAS). 2 Precise thermal injury to these structures is thought to result in immediate contraction of denatured collagen, initiation of neocollagenesis, and finally delayed collagen remodeling. 3 The global wound healing and collagen remodeling are believed to contribute to clinically significant tightening of tissues in the face, neck and décolleté, as well as softening of wrinkle lines. [4] [5] [6] [7] Although several studies 8, 9 have demonstrated that more treatment lines (higher joule energy) at 2 or 3 tissue planes resulted in significantly greater lifting, there have been no split-face studies to verify the efficacy and safety of these newer algorithms.
The purposes of this randomized split-face study were twofold. Pilot study 1 assessed the effectiveness and safety of 2 tissue planes of similar treatment depths with differing number of treating lines (joule energies) to split marionette folds. Pilot study 2 evaluated the effectiveness of identical number of treatment lines (joule energies) in 2 tissue planes with the addition of a third more superficial dermal plane to one of the split marionette folds. From these results, the author customized algorithmic treatments based on clinical assessments and expectations and evaluated the safety and efficacy with these treatment variations in his clinical practice.
METHODS

Study Protocols (Assessment and Selection Criteria)
Study patients were treated in compliance with guidelines established by the approving institutional review board (IRB) (Asentral, Inc., Newburyport, MA) for pilot study 1 and pilot study 2, and regulations established by the International Organization for Standardization and US Food and Drug Administration. Of over 100 adults recruited in 3 months (April-June 2014) from the study site's patient database, only 20 patient were qualified, provided written informed consents, and randomized into one of 2 pilot study groups of 10 patients, based on either their odd or even chart numbers. Ten patients with odd file-chart numbers were placed in pilot study 1, while 10 patients with even-file chart numbers were sorted into pilot study 2. In order to minimize further treatment bias, 5 patients in pilot study 1 with odd numbers on enrollment (group A: 1, 3, 5, 7, and 9) received a lower number of treatment lines to their right marionette folds and a higher number of treatment lines to their left marionette folds. In contrast, 5 patients with even numbers on enrollment (group B: 2, 4, 6, 8, and 10) were slated to receive a higher number of treatment lines to their left marionette folds and a lower number of treatment lines to their right marionette folds. In pilot study 2, all 10 patients received identical treatment lines to 2 planes of treatment to both marionette folds. In order to minimize treatment bias, patients enrolled with odd numbers (group A: 1, 3, 5, 7, 9) received treatment at a third plane to their right marionette folds, while patients enrolled with even numbers (group B: 2, 4, 6, 8, 10) received treatment at a third plane to their left marionette folds.
Inclusion criteria included mild-to-moderate ptosis of skin and fibro-muscular layers, as well as mild-to-moderate fat thickness to the marionette folds. Exclusion criteria included severely damaged actinic skin, thin porcelain skin, significant ptotic skin and fibro-muscular units, active systemic or local infections, acne or keloidal scarring, skin diseases altering wound healing, hemorrhagic disorders or hemostatic dysfunctions, and pregnant or breast-feeding women. Patients, who had undergone facial surgeries, including ablative and nonablative skin procedures, were excluded until a year after their procedures.
Pretreatment IRB Protocols
One week prior to treatment, the usage of topical skin care products such as retinoic acid, glycolic acid, and salicylic acid was discontinued. On the day of treatment, the application of facial creams, lotions, powders, and foundations was avoided. Patients washed their faces with a mild cleanser prior to their procedure. All metal jewelry was removed from the facial area. Patients with a history of viral infections were placed on prophylactic antivirals 2 days prior and 6 days after completion of the procedure.
Baseline photographic documentation, special matched-orientation photographs for tissue displacement, and skin elasticity measurements were obtained as described in the Photographic and Statistical Analysis section. Two 2.5 × 2.5 cm 2 squares were marked in the selected treatment sites for pilot studies 1 and 2, as depicted in Figure 1 . The predicted exposed pathway of the marginal mandibularis rami (medial to the marionette line) was outlined to avoid the placement of any treatment lines, as recommended in the manufacturer's Treatment Reference Guide. 10 Treatment was also avoided directly over areas with mechanical implants, electrical devices, and soft tissue augmentation materials.
Treatment Protocol
A full description of the ultrasound system used in this study is found at FDA.gov (Ulthera System; Ulthera, Inc. Mesa, AZ; approved by the US Food and Drug Administration in September 2009). The treatment designs for pilot study 1 and pilot study 2 were altered to isolate effects at the marionette folds but complied with the overall treatment algorithm and techniques stated in the Guideline Booklet 10 on the safety and efficacy in patients treated at higher and lower number of treatment lines (joule energies) at 2 or 3 tissue planes.
After a thin layer of ultrasound transmission gel was applied to the facial skin surface, the selected transducer was positioned on the marked skin treatment square and activated to begin imaging of the skin and subdermal structures. On activation of the transducer, a series of thermal coagulation points (TCP) were deposited at the selected tissue level in a straight line. This sequence was repeated within each treatment square with the selected number, direction, and depth of overlapping (1-2 TCPs) treatment lines, depending on the study protocols to complete the procedure. The ultrasound transmission gel was reapplied frequently to ensure proper tissue imaging and coupling. For occasional patients who acknowledged having low pain thresholds or experienced moderate discomfort during treatment, a pain management program was initiated in a graded fashion. A standard pain management program incorporated the use of an oral analgesic (Ibuprofen 800 mg) and a distractive vibrating hand device. Lowering skin temperatures by an air coolant device, using selective nerve blocks or subcutaneous infiltration of buffered lidocaine, or reducing joule energy and length of treatment lines were not employed in any patient. After completion of treatment and removal of the ultrasound gel, all patients were able to return to their usual lifestyle and activities. Medical skin care regimens resumed within a week. Pilot study 1 began in May 6, 2014 and ended on January 26, 2016. Pilot study 2 occurred between May 29, 2014 and December 15, 2015.
Pilot Study 1 Algorithm
Ten patients were scheduled for single treatments to opposing marionette folds in a similar fashion but with more treatment lines at one marionette fold vs a lower number of treatment lines on the opposing side ( Table 1) . Patients were to be treated on 2 marked 2.5 cm 2 × 2.5 cm 2 squares at each side of the marionette lines. Enrolled patients were assigned to one of 2 groups in order to minimize treatment bias, based on their order of enrollment, as follows. 
Pilot Study 2 Algorithm
Ten patients were indicated for identical treatments at 2 tissue planes to each marionette fold, but one of the folds was randomized to receive a third more superficial dermal treatment plane (Table 1) . Patients were to receive single treatments to marked two 2.5 cm 2 × 2.5 cm 2 squares on each side of the marionette lines. Enrolled patients were assigned to one of 2 groups in order to minimize treatment bias, based on their order of enrollment, as follows. 
Posttreatment Assessment Protocol for Pilot Study Patients
At 180 days post treatment (D180) and 360 days post treatment (D360), patients repeated their standardized photographs, matched-orientation photographs for tissue displacement, and skin elasticity measurements for comparison statistical analyses. At the end of the one-year study, patients assessed their own results from their standardized photographs taken at baseline, D180, and D360, based on a Subject Global Aesthetic Improvement Scale (SGAIS), as described in the Photographic and Statistical Analysis section.
Clinical Protocol for Off-Study Patients
In the author's general practice, MFU-V treatments were indicated for mild-modest tightening and lifting of tissues in patients undergoing: (1) a nonsurgical technique for aesthetic improvements; (2) possible correction of incomplete surgical skin results; (3) MFU-V therapy in combination with other aesthetic procedures (intense pulse light, resurfacing, microneedling, muscle relaxants, and volumizers). Prospective patients were indicated for customized treatments at either dual or triple tissue planes based on clinical findings and expectations to rejuvenate aging signs at their forehead, periorbitum, face, neck, and décolleté. After patients satisfactorily met their inclusion criteria and had their standardized photography, as described in the Pilot Studies sections, the author decided on the customized treatment plan arbitrarily based on clinical findings, patients' goals, and safe delivery of energy at each regional site. The number and distribution of treatment lines adhered to the recommended mapping and treatment algorithms in the Treatment Reference Guide, 10 making multiple passes and moving between columns as necessary, based on the patient's response. Patients with skin laxity were advised to receive dermal treatments at either one or 2 planes based on the author's perception of degree of laxity. Patients with more equivalent gradations of skin and subdermal laxity (marionette folds and jowls) were advised to receive treatments at the dermal planes (DS7 MHz-3.0 mm; DS10 MHz-1.5 mm) and the subdermal plane (DS4 MHz-4.5 mm). The forehead and periorbital regions represented specialized areas where the DS4 MHz-4.5 mm transducer was not used because of: (1) the thinness of tissue planes; (2) potential injury to the superficial frontal branches of the facial nerve; and (3) increased pain from thermal reflection off bony surfaces. Energy treatment was avoided directly over the eye, thyroid gland and trachea, and exposed tracts of the frontal and marginal mandibularis nerve branches. Treatments were delivered with precautions directly over bone and major vessels because of potential thermal complications. Ultrasonic imaging was used at all times to verify location and depth of treatment lines. The maximum length of 25 mm for treatment lines and maximum default energy settings (DS4 MHz-4.5 mm, 1.2 joules; DS7 MHz-3.0 mm, 0.45 joules; DS10 MHz-1.5 mm, 0.25 joules) were selected as much as possible for all treatments. The pretreatment protocol for avoidance of skin products and metal jewelry, skin 3e3e3e preparation.
Photographic and Statistical Analysis
In pilot studies 1 and 2, a dedicated medical photographer-computer analyst used a custom-designed Canfield photographic system (Canfield Scientific, Inc., Parsippany, NJ) for baseline and follow-up photography at D180 and D360 with standardized lighting (0°, 45°, and 90° views).
The matched-orientation function of the Mirror software compared baseline and posttreatment distance changes (mm) between reference points on a standardized facial positioning table. Each photographic image was automatically tagged with a specific label (metadata) that could not be edited. An average of 3 superolateral displacements of each marionette line along a fixed reference line (extending from inferior tragal notch to midpoint of marionette line) compared measurements for each patient and between each group. A disadvantage of using the marionette fold as a reference point for measurements was the inherent vagary of mobile structures. However, data were subjected to 1-way analysis of variance to test for significance between and within groups and for homogeneity of variances. Data were analyzed using comparisons of mean differences, standard errors, and 95% significance at a probability level of 0.05. For patients in the pilot studies, the DermaLab SkinLab Combo Module with Cortex Technology (Hadsund, Denmark) used an elasticity vacuum probe that measured the skin's viscoElasticity (VE) at baseline, D180, and D360. The patients were acclimated to the ambient environment for a period of thirty minutes prior to the procedure. The device was calibrated by the manufacturer with a declaration of conformity prior to initiation of this study. The measurement site was marked using a standard template to ensure that the vacuum probe was positioned in the same place at each visit. One technician, experienced in the Cortex technology, performed all DermaLab skin measurements. Data were subjected to 1-way analysis of variance to test for significance between and within groups and for homogeneity of variances. Data were analyzed using post hoc tests for multiple comparisons of mean differences, standard errors, and 95% significance at a probability level of 0.05.
Two blinded medical assistants, who were not involved in the pilot studies, rated aesthetic efficacy and safety at the marionette folds in pilot-study patients at D180 and D360, and off-study patients at D360 from photographs, using a validated Investigator Global Aesthetic Improvement Scale (IGAIS) comparing standardized pre-and posttreatment photographs: 1 = very much improved; 2 = much improved; 3 = improved; 4 = no change; 5 = worse. In the surgeon's office, patients in pilot studies 1 and 2 rated their own results at the marionette folds by examining their photographs at baseline, D180, and D360, using a validated Subject Global Aesthetic Improvement Scale (SGAIS) comparing their pre-and posttreatment standardized photographs: 1 = very much improved; 2 = much improved; 3 = improved; 4 = no change; 5 = worse. Data were subjected to 1-way analysis of variance to test for significance between and within groups and for homogeneity of variances. Data were analyzed using post hoc tests for multiple comparisons of mean differences, standard errors, and 95% significance at a probability level of 0.05.
Two provider registered nurses, who treated the patients, recorded perceived pain level during each treatment with individual transducers and globally at the end of the session, based on a validated 10-point numeric rating pain scale (NRPS): 0 = no pain; 2.5 = mild pain; 5 = moderate pain; 7.5 = intense pain; 10 = intolerable pain. The same 2 providers recorded perceived pain levels, as stated by off-study patients, during the individual use of the 3 transducers and also a global pain response after completion of treatment at either, single, dual, or triple tissue planes in each of the geographic areas of the forehead, periorbitum, face, neck, and décolleté. Knowledge of the impact roles that treatment sites, tissue treatment plane, amount of joule energy/TCP, and treatment lines contribute to the production of pain sensation during treatment may suggest possible means to ameliorate this undesirable effect yet experience a safe and effective treatment. Data were subjected to 1-way analysis of variance to test for significance between and within groups and for homogeneity of variances. Data were analyzed using the post hoc analyses probability level of 0.05.
RESULTS
The demographic data of patients in pilot studies 1 and 2 and off-study patients are summarized in Table 2 which provides their distribution of gender, ages, and ethnicities.
Matched Photographic Displacement Analyses
In pilot study 1 (Table 3) , one patient in group B withdrew before any treatments were begun, leaving 5 patients in group A and 4 patients in group B for evaluation at D180. Post hoc analyses of these 9 patients demonstrated no significant differences between reduced number of treatment lines and higher number of treatment lines. At D360, two patients in group B were no-shows, leaving a total of 7 patients in groups A and B to be evaluated. Although the number of patients is small for statistical analysis, post hoc analyses of these 7 patients resulted in a statistically significant greater displacement of marionette folds (18.8% ± 2.9%; P > 0.05), receiving higher joule-energy levels (45 lines/2.5 cm 2 × 2 squares) than that displacement observed at contralateral marionette folds (10.5% ± 2.4%; P > 0.05), receiving lower joule energy (30 lines/2.5 cm 2 × 2 squares) (Figure 2) .
In pilot study 2 (Table 3) , one patient in group B withdrew before any treatments were begun, while one patient in group A withdrew after her evaluation at D90, leaving a total of 4 patients in group A and 4 patients in group B for evaluation at D180. Post hoc analyses of these 8 patients showed that marionette folds, receiving treatment at three tissue planes, demonstrated a statistically significant displacement (4.4% ± 2.4%; P > 0.05) than that determined on contralateral marionette folds (1.9% ± 1.0%; P > 0.05), treated with identical joule energy at 2 tissue planes (without the added superficial level of treatment with the DS10 MHz-1.5 mm transducer). At D360, a total of the same 4 patients in group A and 4 patients in group B were available for evaluation. Post hoc analyses demonstrated that 8 patients, treated at 3 tissue planes, resulted in significant tissue displacement (5.4% ± 2.3% P > 0.05) than that observed on the opposite side treated at two tissue planes (2.6% ± 1.5%; P > 0.05) (Figure 3 ).
Elasticity Analyses
In pilot study 1 (Table 3) , the same 7 patients that underwent matched photographic displacement measurements were available at D180 and at D360 for Cortex elasticity measurements. Post hoc analyses resulted in no statistically significant difference in percent elasticity changes after 30 lines vs 45 lines at D180 (11.1% ± 7.7% MPa units; 18.4% ± 16.5% MPa units; P > 0.05) and at D360 (25.3% ± 14.0% MPa units; 27.5% ± 8.8% MPa units; P > 0.05), respectively.
In pilot study 2 (Table 3) , the same 8 patients, that underwent matched photographic displacement measurements, were available at D180 and D360 for Cortex elasticity measurements. Post hoc analyses resulted in a statistically significant difference in percent elasticity changes after treatment of 2 vs 3 tissue planes at D180 (33.6% ± 15.7% MPa units; 44.0% ± 28.9% MPa units; P < 0.05) and at D360 (36.5% ± 17.2%; 54.6% ± 22.1% MPa units; P < 0.05), respectively.
Patient Satisfaction Scores
Each pilot study 1 or 2 patient rated his/her own SGAIS satisfaction outcome at the marionette folds, based on a visual analogue scale, comparing pretreatment photographs to posttreatment photographs on D180 and D360, listed in Table 4 . Pilot study 1 patients assessed their outcomes at D180 as "improved" results with 30 lines (3.0 ± 2.0) and with 45 lines (3.0 ± 2.0), respectively, and "much improved" with 30 lines (2.0 ± 1.8) and with 45 lines (2.0 ± 2.0), respectively, at D360. Pilot study 2 patients assessed their SGAIS satisfaction outcomes as "improved" results with 2 treatment levels (3.0 ± 1.5), but observed "much improved" results with 3 treatment levels (2.0 ± 1.5) at D180. At D360, patients assessed their SGAIS satisfaction ratings as "improved" results with 2 treatment levels (3.0 ± 2.1), but observed "much improved" results with 3 treatment levels (2.0 ± 1.4).
Investigator Satisfaction Scores
Two blinded investigators (medical assistants) also assessed changes to the marionette folds from pretreatment to posttreatment photographs of patients in pilot studies 1 and 2 at D180 and D360 (Table 4) . IGAIS satisfaction outcomes in the pilot study 1 patients were assessed ratings of "improved" results on the sides of DS4 MHz-4. , respectively, at D180 and ratings of "improved" results (3.0 ± 1.2 at two levels; 3.0 ± 1.0 at three levels), respectively at D360.
Off-Study Patient Satisfaction Scores
Two blinded investigators' IGAIS scores at D360 for offstudy clinical patients rated "improved" results (3.0 ± 2.2; 3.0 ± 2.1) at two treatment levels to the forehead and periorbitum, respectively, and "improved" results (3.0 ± 2.4; 3.0 ± 2.2; 3.0 ± 0.4) at three treatment levels to the face, neck, and décolletage, respectively listed in Table 4 ( Figures 4 and 5 ). An attempt to obtain SGAIS evaluations from the large cohort of off-study patients was unsuccessful because of the large number of nonresponders to questionnaires.
Pain Analyses in Pilot Studies 1 and 2 and Off-Study Patients
Patients were asked to report to their providers their levels of pain at the end of treatments to the two marked 2.5 cm 2 squares adjacent to the marionette lines (Table 5 ). Post hoc analyses of 9 patients in pilot study 1 recorded statistically nonsignificant differences in perception of cumulative end pain after 30 line vs 45 line treatments at 2 tissue treatment planes (4.0 ± 1.2; 5.5 ± 1.7), respectively. Treatment always started at the deepest level with the DS4 MHz4.5 mm transducer followed by the more superficial layer of injury with the DS7 MHz-3.0 mm transducer. Post hoc analyses of data from 8 patients in pilot study 2 showed greater but statistically nonsignificant differences in perception of cumulative end pain after 2 vs 3 treatment planes (6.0 ± 1.9, 8.3 ± 3.0), respectively. Although a few patients in the pilot study 2 group experienced "intense pain" levels, all patients in both pilot study groups were able to complete their treatment algorithms. None of the patients reported any pain discomfort after a few days. In contrast to the above mentioned pain perception at the marionette folds from patients in pilot study groups 1 and 2, off-patients' perception of pain were wide ranging because of customized treatments to different anatomic sites, as summarized in Table 5 . In general, off-patients rated their entire pain experience at the end of single treatment planes (DS7 MHz-3.0 mm) to the forehead (8.0 ± 3.5) and periorbitum (6.3 ± 3.3), respectively, to be the among the most sensitive treatment sites. When asked to judge levels of pain after the use of each transducer during 2 planes of treatment in the forehead and periorbitum, off-study patients experienced slightly greater discomfort after use of the DS10 MHz-1.5 mm transducer (8.8 ± 4.0; 8.3 ± 3.8), respectively than after the use of the DS7 MHz-3.0 mm transducer (8.0 ± 3.5; 7.3 ± 3.1), respectively. End-pain levels assessed after combined 2 level treatments were similar to that experienced after individual levels of treatment in these sensitive areas. Off-study patients felt greater sensitivity after individual use of the DS4 MHz-4.5 mm transducer to the face (6.0 ± 2.3), neck (6.8 ± 2.8), and décolleté (4.0 ± 1.2) than after the use of the more superficial middermal plane of the DS7 MHz-3.0 mm transducer to the face (2.8 ± 0.5), neck (6.0 ± 2.3), and décolleté (3.5 ± 1.0). In general, end-pain assessment after 2 level combined treatment to the face, neck, and décolleté was similar to treatments with individual transducers.
Of interest, the level of end pain in off-study patients was about the same after treatment at 2 or 3 treatment planes. When asked to assess levels of pain after the use of each transducer during 3 planes of treatment, patients experienced greater sensitivity after the use of the DS4 MHz-4.5 mm to the face (5.5 ± 2.1), neck (6.8 ± 3.0), and décolleté (5.5 ± 2.1) than after the use of the more superficial middermal DS7 MHz-3.0 mm to the face (2.8 ± 0.5), neck (4.5 ± 1.5), and décolleté (4.5 ± 1.5). The addition of the most superficial dermal DS10 MHz-1.5 mm resulted in the highest perception of pain to the face (6.8 ± 2.8), neck (7.0 ± 2.9), and décolleté (6.5 ± 2.6).
Side Effects and Complications
None of the patients in pilot studies 1 and 2 or in offstudy patients in the clinical study experienced any significant short-or long-standing adverse events, such as prolonged sensory dysesthesias, permanent paresis/paralysis, blistering, ulceration, scarring, or dyschromia at the D180 and D360 evaluation periods. All patients completed treatments and received follow-up examinations and photo documentations. Although all participants experienced pain during treatments, none of them required local anesthesia or nerve blocks to complete treatment protocols. Transient discomfort occurred during the procedure but disappeared immediately after the heat energy dissipated. However, about 5% (14 patients) of off-study patients, especially those treated at 3 levels, experienced low grade pain or hypersensitivity for more than a week after treatment. Transient erythema was observed for 1 to 2 hours along with mild swelling for several days in all treated areas. Striated linear line patterns were observed 
DISCUSSION
Since 2007, MFU-V 1-9 has become an established technology for noninvasive skin and subdermal lifting and tightening compared to other heating devices, using radiofrequency, 11-14 infrared, 15, 16 and other energy sources. 17, 18 The proliferation of these skin tightening devices continues to address the inconsistencies in clinical outcomes, discomfort in application, and cost. Informed patients often preferred such noninvasive treatments over invasive devices or surgeries as they offer acceptable outcomes in combination with fillers and muscle relaxants and are associated with minimal downtime and morbidity.
Unique features of MFU-V are attributed to its ability to deliver precise geometrically microfocused ultrasound energy packets at precise and consistent depths on potentially 3 tissue planes, which extend from the superficial dermis, mid-to-low dermis, and even the subdermal connective tissue of septae and the SMAS system. By manipulating ultrasound energy, focal depth, and vectoring lines, MFU-V has the potential to be customized to meet the different physical characteristics of each patient. 8, 19 A previous study 4 reported that the use of MFU-V has been associated with collagen changes in the treated area. Dosedependent thickening and collagen contraction has been observed in cadaver facial tissue, 3 while tissue biopsies 4 revealed a 23.7% increase in collagen in the reticular dermis.
In the present investigations, post hoc analyses in pilot study 2 at D180 and D360 showed that patients receiving a greater number of treatment lines and joule energy at 3 tissue treatment planes achieved significantly greater tissue displacement, as measured by Canfield matched-orientation analyses, compared to lesser displacements of the contralateral marionette folds, treated at 2 tissue planes. Explanations for the beneficial displacement results, observed in patients in pilot study 2, could be extrapolated from the Cortex elasticity analyses at D180 and D360 that found greater positive changes in skin elasticity with the addition of the third superficial dermal plane as compared to observed skin elasticity changes to identical joule energies and treatment lines with dual treatment planes. These observations suggest that the addition of superficial dermal treatment lines (DS10 MHz-1.5 mm) may provide greater skin tightening than that observed with dual treatment planes The purported benefits of providing more controlled thermal energy to the skin with the 2 dermal transducers (DS7 MHz-3.0 mm; DS10 MHz-1.5 mm) rather than to the subdermal tissues with the DS4 MHz4.5 mm transducer at this specific treatment site will require further investigations to optimize customized MFU-V treatments to address the patient's physical findings. In contrast, post hoc Canfield matched-orientation analyses of marionette fold displacement in pilot study 1 at D180 and D360 demonstrated mixed results when compared to matched-orientation analyses in pilot study 2 patients. Although no statistical significant difference between lower number of treatment lines (less joule energy) and higher number of treatment lines (greater joule energy) was observed at D180, there appeared to be a statistical significant tissue displacement by D360 when more treatment lines and joule energy were delivered. These results suggest that higher joule-energy treatments to the mid-dermal and subdermal planes may take longer to observe greater tissue displacement than that seen with less treatment lines and joule energy by D180 and D360. The observation from Cortex elasticity analyses at D180 and D360, that demonstrated no statistically significant differences in percent elastic changes in the 2 groups, provided further evidence of a limitation of benefits with increasing treatment lines and joules energy over the recommended treatment algorithm.
One of the objectives of this study was to demonstrate aesthetic outcomes up to one year after single MFU-V treatment sessions with differing algorithms in split-treatment protocols. The objectives were met based on SGAIS and IGAIS D180 and D360 assessments in the present studies and reflected in the D360 IGAIS assessments in the off-study clinical patients. These encouraging outcomes support the recommended treatment algorithms in providing positive and safe effects at least a year after single treatments of increased joule energy and 3 treatment planes. The significance of thermal discomfort experienced by our patients during treatments is critical to the overall acceptance of the procedure in terms of safety, tolerability, and optimizing efficacy and costs. The greater degree of thermal pain perceived may lead not only to patient reticence for treatments, but also to thermal skin changes, such as erythema, blisters, partial thickness burns, and possible deeper injuries to the subcutaneous fat and nerves. The more lines (joule energy) and tissue planes treated can result in greater time for the procedure and increased patient cost. Our experience suggested that the perception of pain intensity by each patient was variable. In general, treatments with greater joule energy (increased lines of treatment) were perceived to higher levels of discomfort but oftentimes reflected regional variations of soft tissue thickness and bony prominences. The more tissue planes treated resulted in a greater perception of pain, especially with the most superficial treatment level with the 1.5 mm transducer. Oftentimes, the pain level experienced after individual treatments with different transducers equaled the combined perception of pain at the end of treatment. Overall, more aggressive pain control by our pain management program and/or by lowering the joule-energy levels (less treatment lines) and perhaps the selection of dual rather than triple treatment planes may be associated with less discomfort without significantly compromising tolerance, safety, and efficacy. The MFU-V system and the treatment algorithms in this study continue to demonstrate a very acceptable safety profile despite the encountered moderate to high levels of pain. The potential limitations of pilot studies 1 and 2 involved the small cohort of patients that were evaluated, as well as appropriate criteria for patient selection and realistic expectations. Future larger studies will be needed to delineate the significance of the use of each parameter separately or in combination with serial treatment plans. The preliminary results of this study need to be validated with a larger number of patients and from unbiased data with multicenter trials.
CONCLUSION
This research demonstrated the potential of optimizing and customizing single standardized treatment algorithms to lift and tighten tissues at either 2 or 3 treatment planes in split-face studies by matched-orientation displacement photography, elasticity measurements, and SGAIS and IGAIS satisfaction criteria. Pain assessment was analyzed with the use of each of 3 transducers separately and together to provide tolerable, safe, and effective treatment guidelines. The study demonstrated an acceptable safety profile with a low incidence of shortterm side effects.
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